Similar articles

• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H. Polman CH, et al. Neurology. 2007 Oct 9;69(15):1553-4; author reply 1555. doi: 10.1212/01.wnl.0000295671.79239.f1. Neurology. 2007. PMID: 17923619 No abstract available.
• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Pachner AR. Pachner AR. Neurology. 2007 Oct 9;69(15):1555; author reply 1565. doi: 10.1212/01.wnl.0000295672.17358.95. Neurology. 2007. PMID: 17923620 No abstract available.
• Interferon neutralizing antibodies in multiple sclerosis: a new perspective.

  Phillips JT. Phillips JT. Arch Neurol. 2010 Apr;67(4):386-7. doi: 10.1001/archneurol.2010.31. Arch Neurol. 2010. PMID: 20385901 No abstract available.
• Implications of neutralising antibodies on therapeutic efficacy.

  Bertolotto A. Bertolotto A. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S29-32. doi: 10.1016/S0022-510X(09)70009-7. J Neurol Sci. 2009. PMID: 19200862 Review.
• Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2008 Sep 2;71(10):766-73. doi: 10.1212/01.wnl.0000320512.21919.d2. Neurology. 2008. PMID: 18765653 Review.